Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash from Financing Activities: 2018-2024

Historic Cash from Financing Activities for Arcturus Therapeutics Holdings (ARCT) over the last 7 years, with Dec 2024 value amounting to $5.4 million.

  • Arcturus Therapeutics Holdings' Cash from Financing Activities rose 76.77% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 113.67%. This contributed to the annual value of $5.4 million for FY2024, which is 122.49% up from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Cash from Financing Activities of $5.4 million as of FY2024, which was up 122.49% from -$24.1 million recorded in FY2023.
  • Arcturus Therapeutics Holdings' 5-year Cash from Financing Activities high stood at $436.1 million for FY2020, and its period low was -$24.1 million during FY2023.
  • For the 3-year period, Arcturus Therapeutics Holdings' Cash from Financing Activities averaged around -$7.2 million, with its median value being -$2.9 million (2022).
  • Per our database at Business Quant, Arcturus Therapeutics Holdings' Cash from Financing Activities soared by 940.74% in 2020 and then crashed by 742.50% in 2023.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Cash from Financing Activities (Yearly) stood at $436.1 million in 2020, then tumbled by 88.99% to $48.0 million in 2021, then slumped by 105.95% to -$2.9 million in 2022, then plummeted by 742.50% to -$24.1 million in 2023, then surged by 122.49% to $5.4 million in 2024.